Mode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (Nelumbo nucifera) against Multidrug-Resistant Tumor Cells

Onat Kadioglu¹, Betty Y. K. Law², Simon W. F. Mok², Su-Wei Xu², Thomas Efferth¹* and Vincent K. W. Wong²*

¹ Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany,
² State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China

Neferine, a bisbenzylisoquinoline alkaloid isolated from the green seed embryos of Lotus (Nelumbo nucifera Gaertn), has been previously shown to have various anti-cancer effects. In the present study, we evaluated the effect of neferine in terms of P-glycoprotein (P-gp) inhibition via in vitro cytotoxicity assays, R123 uptake assays in drug-resistant cancer cells, in silico molecular docking analysis on human P-gp and in silico absorption, distribution, metabolism, and excretion (ADME), quantitative structure activity relationships (QSAR) and toxicity analyses. Lipinski rule of five were mainly considered for the ADME evaluation and the preset descriptors including number of hydrogen bond donor, acceptor, hERG IC₅₀, logp, logD were considered for the QSAR analyses. Neferine revealed higher toxicity toward paclitaxel- and doxorubicin-resistant breast, lung or colon cancer cells, implying collateral sensitivity of these cells toward neferine. Increased R123 uptake was observed in a comparable manner to the control P-gp inhibitor, verapamil. Molecular docking analyses revealed that neferine still interacts with P-gp, even if R123 was pre-bound. Bioinformatical ADME and toxicity analyses revealed that neferine possesses the druggability parameters with no predicted toxicity. In conclusion, neferine may allocate the P-gp drug-binding pocket and prevent R123 binding in agreement with P-gp inhibition experiments, where neferine increased R123 uptake.

Keywords: cancer, chemotherapy, drug resistance, natural products, neferine, P-glycoprotein

INTRODUCTION

The main characteristics of cancer are uncontrolled growth and metastasis of mutated cells ultimately leading to the death of patients (Stratton et al., 2009). The World Health Organization (WHO) estimated around 8.2 million deaths and 14.1 million newly diagnosed cancer cases in 2012 worldwide. According to American Cancer Society reports, 1,688,780 new cancer cases and
600,920 cancer deaths are projected to occur in the United States in Siegel et al. (2017). Remarkably, underdeveloped countries had the largest incidence of new cases (8.0 million) and the highest death rates (5.3 million). Lifestyle risk factors such as smoking, obesity and physical inactivity will probably cause a further increase in cancer cases in the future (Jemal et al., 2011).

Chemotherapy is one of the mainstays of cancer management, often performed by simultaneously administering combination regimens of various agents. However, the success rate is limited due to drug resistance of tumor cells and high treatment-related toxicities (Jabour et al., 2009; Eghtedar et al., 2013). Owing to severe side effects, chemotherapeutic drugs cannot be administered in doses high enough to reliably eliminate all tumor cells in the body, leading to narrow therapeutic indices.

In addition to severe toxicity, MDR represents a main problem of chemotherapy failure. MDR is characterized by cross-resistance to many structurally and mechanistically unrelated anticancer drugs (Gottesman and Ling, 2006; Gillet et al., 2007; Kuete et al., 2015). P-glycoprotein (P-gp) encoded by the ABCB1/MDR1 gene is upregulated in many clinically resistant and refractory tumors and is referred as one of the most important mechanism of MDR (Kuete et al., 2015). Overexpression of P-glycoprotein (P-gp) is linked to accelerated efflux of chemotherapeutic agents. This process is fueled by ATP as energy source to perform the drug efflux. Targeting P-gp and other efflux pumps of the ABC transporter family represents a promising strategy to revert MDR and increase the efficiency of chemotherapy drugs (Abdelfatah and Efferth, 2015). The elucidation of the crystal structure of murine P-gp (Aller et al., 2009) and the development of homology models of human P-gp based on the murine amino acid structure have yielded valuable information to better understand poly-specific drug-binding in multiple conformations of P-gp (Aller et al., 2009; Zeino et al., 2014; Kadioglu et al., 2016).

In an endeavor to develop novel drugs with higher tumor specificity and lower toxicity to normal tissues, natural products serve as valuable source (Newman and Cragg, 2012; Cragg and Newman, 2013). Biosynthesis of natural products depends either on evolutionary adaption to the surrounding environments or as defense mechanism for the survival of organisms (Maplestone et al., 1992; Efferth et al., 2007). They can be of plant, animal, marine, or microorganismic origin. The bioactivity of natural products is based on the assumption that they possess specific activity toward different target proteins (Venkataraman, 2010). The challenging task of pharmacology is to identify disease-related targets that are relevant for therapeutic intervention in human patients (Cragg and Newman, 2013). Around 75% of approved anticancer agents are indeed based on natural products (Newman and Cragg, 2012; Cragg and Newman, 2013), which is a strong hint that natural products represent a promising reservoir for drug development.

Neferine is a bisbenzylisoquinoline alkaloid isolated from the green seed embrios of Lotus (Nelumbo nucifera Gaertn). This plant has been consumed in India and China since ancient times. In traditional Chinese medicine, it has been widely used to treat nervous disorders, insomnia, high fevers with restlessness, as well as pulmonary and cardiovascular diseases such as hypertension, atherosclerosis, restenosis, and arrhythmia (Sridhar and Bhat, 2007; Jun et al., 2016; Sharma et al., 2017). Various studies pointed out the potential anti-cancer effect of neferine as well (Huang et al., 2011b; Yoon et al., 2013; Poornima et al., 2014; Xu et al., 2016). In this study, we evaluated the effect of neferine in terms of P-gp inhibition via in silico molecular docking, QSAR and in vitro cytotoxicity assays and P-gp substrate uptake assays in drug-resistant cancer cells.

**MATERIALS AND METHODS**

**Cell Culture**

All cells were obtained from the American Type Culture Collection (Rockville, MD, USA) unless otherwise specified. Taxol and doxorubicin-resistant types of MCF-7, A549 and HCT-8 cancers cells were purchased from KeyGEN BioTECH, China. All media were supplemented with 10% fetal bovine serum and the antibiotics penicillin (50 U/ml) and streptomycin (50 µg/ml; Invitrogen, Paisley, Scotland, UK). All cell cultures were incubated at 37°C in a 5% humidified CO2 incubator.

**Cytotoxicity Assays**

Neferine was dissolved in DMSO at final concentrations of 100 mmol/L and stored at −20°C before use. Cytotoxicity was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (5.0 mg/ml) assay. Briefly, 4 × 10^3 cells were seeded per well in 96-well plates before drug treatment. After overnight culture, the cells were then exposed to different concentrations of neferine (0.039–100 µmol/L) for 72 h. Cells without drug treatment were used as control. Subsequently, MTT (10 µL) was added to each well and incubated at 37°C for 4 h followed by the addition of 100 µL solubilization buffer (10% SDS in 0.01 mol/L HCl) and overnight incubation. A_{570 nm} was determined from each well on the next day. The percentage of cell viability was calculated using the following formula: Cell viability (%) = A_{treated}/A_{control} × 100. Data were obtained from three independent triplication experiments. Mean represented as ± SD. The IC50 value is directly obtained from the intercept between the growth curve and a horizontal line at 50% of viability in prism graph.

**Molecular Docking**

The previously generated homology model of human P-gp (Tajima et al., 2014) was used for molecular docking studies with AutoDock 4 (Morris et al., 2009) on the drug-binding pocket. The residues at the drug-binding pocket were His61, Gly64, Leu65, Met69, Ser222, Leu304, Ile306, Tyr307, Phe336, Leu339, Ile340, Ala342, Phe343, Gln725, Phe728, Phe732, Leu762, Thr837, Ile868, Gly872, Phe942, Thr945, Tyr953, Leu975, Phe978, Ser979, Val982, Gly984, Ala985, Met986, Gly989, Gln990, and Ser993 (Aller et al., 2009). A grid map was chosen to cover these residues. Three independent docking calculations for neferine and R123 were conducted with 2,500,000 evaluations and 250 runs using Lamarckian Genetic Algorithm. The LBEs and predicted inhibition constants were obtained from the docking log files (dlg) and mean ± SD values were calculated. For
visualization of the docking results, visual molecular dynamics (VMDs) were used. VMD software was developed with NIH support by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign. For co-docking calculations, R123 and neferine were selected to evaluate the effect of pre-docked compound on binding energies and docking pose.

**QSAR and Toxicity Prediction**

Stardrop software (Optibrium, Cambridge, UK) was used to evaluate the druggability properties and toxicity of neferine. The ADME QSAR module of Stardrop was used to predict the druggability properties whereas the Derek Nexus module was used to predict the toxicities. ADME QSAR module helps to predict a broad range of ADME and physicochemical properties using a suite of high-quality QSAR models. Derek Nexus module involves a knowledge-based prediction of key toxicities by using data from published and unpublished sources. Derek Nexus identifies structure-toxicity relationships of compounds predicting the potential for toxicity. It calculated the likelihood of a compound causing toxicity based on more than 40 endpoints, including mutagenicity, hepatotoxicity, and cardiotoxicity.

The outputs from ADME QSAR and Derek Nexus modules were compared with that of verapamil. HBD, HBA, MW, logP, logD, TPSA, rotatable bonds, HIA, hERG (potassium channel) IC₅₀, logS, logD, TPSA, number of rotatable bonds) were selected as druggability descriptors. hERG activity is crucial for cardiac action potentials and blockade of hERG is linked with cardiac arrhythmia and cardiotoxicity. The parameters meeting the druggability properties were labeled green (H-bond donor < 5, H-bond acceptor < 10, MW < 500, logP < 5, logD < 5, TPSA < 140, Rotatable bonds < 10) (Veber, 2003; Lipinski et al., 2012). Plausible toxicities were labeled as pink, equivocal toxicities were labeled as yellow, inactive toxicities were labeled as green.

**Rhodamine 123 Exclusion Assay**

The rhodamine 123 exclusion assay was carried out according to the reported procedures (Huang et al., 2012). Briefly, MDR cells were seeded in 6 well plate with 2 × 10⁵ cells each well and cultured for 24 h at 37°C in an atmosphere containing 5% CO₂. At confluence, MDR cells were incubated with or without the modulator (10 µM of verapamil) and drug (1, 2, 5, and 10 µM of neferine) for 4 h at 37°C. Subsequently, 5 µg/mL of R123 was added to each well. At 1 h at 37°C. The accumulation of R123 was stopped by washing the cells five times with ice-cold PBS. The cells were then resuspended in 400 µL PBS for flow cytometry analysis. Intracellular fluorescence was measured using a flow cytometer at an excitation wavelength of 488 nm and emission wavelength of 525 nm. All data acquisition and analysis were performed with CellQuest (BD Biosciences, San Jose, CA, USA) with at least three independent experiments. Results were shown as the mean of fluorescence intensity.

**Statistical Analysis**

The results were expressed as means ± SD as indicated. The difference was considered statistically significant when the p-value was less than 0.05. Student’s t-test analysis was used for comparison among different groups.

**RESULTS**

**Cytotoxicity Assay**

Neferine yielded IC₅₀ values in the low micromolar range for both sensitive and resistant cell lines. Interestingly, the IC₅₀ values for the resistant sub-lines were even lower than those of sensitive cell lines, a phenomenon which is known as collateral sensitivity (Saeed et al., 2013). The results are summarized in Figure 1.

**Flow Cytometry**

Neferine increased R123 uptake in all drug-resistant cell lines (paclitaxel-resistant MCF-7, doxorubicin-resistant MCF-7 breast cancer cells, paclitaxel-resistant A549 lung cancer cells and paclitaxel-resistant HCT8 colon cancer cells) in a comparable manner, as the well-known P-gp inhibitor verapamil did. Even low concentrations (1 and 2 µM) yielded comparable increase in R123 uptake as verapamil (10 µM) in paclitaxel-resistant (Figure 2) or doxorubicin-resistant MCF-7 cells (Figure 3). In paclitaxel-resistant A549 cells, 2, 5, and 10 µM neferine revealed comparable increases of R123 than verapamil (Figure 4). Low neferine concentrations were enough to increase R123 uptake in paclitaxel-resistant HCT8 cells comparable to verapamil (Figure 5).

**Molecular Docking**

Neferine showed a similar docking pose and a higher LBE value (−9.64 ± 0.02 kcal/mol) than R123 (−8.61 ± 0.01 kcal/mol) on the drug-binding pocket of P-gp. In order to assess, whether pre-docking of R123/neferine could interfere with LBE values or docking poses, dockings of R123 and neferine to complexes of P-gp pre-docked with either of them were performed. If R123 was pre-docked, neferine still bound with high affinity (−8.62 ± 0.08 kcal/mol) on a site close to the drug-binding pocket. R123 docked to a neighboring site with lower affinity (−7.91 ± 0.01 kcal/mol), if neferine was bound on P-gp. These results clearly indicate that neferine docked to the drug-binding pocket with higher affinity than the known substrate R123. The results are summarized in Figure 6.

**QSAR and Toxicity Prediction**

Bearing in mind that neferine would be pharmaceutically further developed as P-gp inhibitor, the question arises about the druggability properties and possible toxicity of this compound. Therefore, druggability and toxicities toward normal tissues for neferine were calculated by using the Stardrop software, via established QSAR model to evaluate the ADME properties and toxicities (Table 1). The established P-gp inhibitor, verapamil was used as positive control. Neferine achieved the preset, defined druggability properties (logS, logP, logD, HBD, HBA, TPSA, number of rotatable bonds) within the required limits as described in Section “Materials and Methods.” Values for those druggability properties were labeled bold in Table 1.
Aqueous solubility was estimated by logS and lipophilicity was estimated by logP and logD. This implies that, neferine possesses indeed the required druggability properties as it passed the majority of the ADME properties. However, neferine might cause skin sensitization, as this toxicity class was predicted as “equivocal.” Importantly, mutagenicity toxicity class was predicted to be absent. No other toxicities were indicated by the Stardrop software for neferine. Verapamil was predicted to possibly cause bladder disorders and hERG channel inhibition. Since the predicted IC$_{50}$ value of neferine for hERG inhibition was higher than for verapamil, the risk of cardiotoxicity due to hERG inhibition is less probable for neferine than for verapamil.

**DISCUSSION**

Neferine from green seed embryos of *Nelumbo nucifera* (Gaertn) is a bisbenzylisoquinoline alkaloid with cytotoxicity toward cancer cells (Poornima et al., 2014; Xu et al., 2016). It also revealed cell cycle arrest, apoptosis, endoplasmic reticulum stress, autophagy, as well as anti-angiogenic and anti-migratory effects in human hepatocellular carcinoma cells (Yoon et al., 2013). It also induces apoptosis in human lung cancer cells via the generation of reactive oxygen species (ROS), activation of MAPKs, lipid peroxidation, depletion of cellular antioxidant pools, loss of mitochondrial membrane potential, and intracellular calcium accumulation (Poornima et al., 2014). Another study reported that neferine synergistically reversed MDR in human gastric cancer cells (Huang et al., 2011b).

The present investigation aimed to analyze the inhibition by neferine of P-gp-mediated efflux of R123 in cancer cell lines insensitive to paclitaxel and doxorubicin treatments. R123 is a well-known substrate of P-gp (Kunihara et al., 1998) and its intracellular concentration is positively correlated to the degree of P-gp inhibition. We showed that neferine possesses P-gp inhibitory effect in all drug-resistant cell lines investigated. Of note, the drug-resistant cell lines exhibited collateral sensitivity (hypersensitivity) to neferine as well. Such P-gp-induced sensitivity of cancer cells, which are resistant
MCF-7 paclitaxel-resistant breast cancer cells

![Flow cytometry data for R123 uptake on paclitaxel-resistant MCF-7 cells under various concentrations of neferine.](image)

**FIGURE 2** | R123 uptake assay of neferine on paclitaxel-resistant MCF-7 breast cancer cells. (A) Represented the raw flow cytometry data of (B), while (B) is the quantitative analysis of these flow cytometry data. **p < 0.001.

MCF-7 doxorubicin-resistant breast cancer cells

![Flow cytometry data for R123 uptake on doxorubicin-resistant MCF-7 cells under various concentrations of neferine.](image)

**FIGURE 3** | R123 uptake assay of neferine on doxorubicin-resistant MCF-7 breast cancer cells. (A) Represented the raw flow cytometry data of (B), while (B) is the quantitative analysis of these flow cytometry data. **p < 0.001.
A549 paclitaxel-resistant lung cancer cells

![A549 R123 uptake assay](image)

**FIGURE 4** | R123 uptake assay of neferine on paclitaxel-resistant A549 lung cancer cells. (A) Represented the raw flow cytometry data of (B), while (B) is the quantitative analysis of these flow cytometry data. **∗∗∗** \( p < 0.001 \).

HCT-8 Paclitaxel-resistant colon cancer cells

![HCT-8 R123 uptake assay](image)

**FIGURE 5** | R123 uptake assay of neferine on paclitaxel-resistant HCT8 colon cancer cells. (A) Represented the raw flow cytometry data of (B), while (B) is the quantitative analysis of these flow cytometry data. **∗∗∗** \( p < 0.001 \).
TABLE 1 | Druggability properties and toxicities of neferine and verapamil as predicted in silico by the Stardrop and Derek Nexus softwares.

|                          | Neferine  | Verapamil |
|--------------------------|-----------|-----------|
| logS @ pH7.4              | 4.302     | 2.941     |
| logP                     | 4.432     | 3.790     |
| logD                     | 3.503     | 1.910     |
| 2C9 pKi                  | 5.736     | 5.315     |
| hERG pIC50               | 7.814     | 6.155     |
| BBB log([brain]/[blood]) | 0.2118    | 0.35      |
| HIA category             | +         | +         |
| P-gp category            | Yes       | Yes       |
| 2D6 affinity category    | Low       | Low       |
| PBP90 category           | Low       | Low       |
| MW                       | 624.8     | 454.6     |
| HBD                      | 1         | 0         |
| HBA                      | 8         | 6         |
| TPSA                     | 72.86     | 63.95     |
| Flexibility              | 0.1961    | 0.4118    |
| Rotatable bonds          | 10        | 14        |
| Phototoxicity            | N.R.      | N.R.      |
| Photostability           | N.R.      | N.R.      |
| Skin sensitization       | Equivocal | N.R.      |
| Occupational asthma      | N.R.      | N.R.      |
| Respiratory sensitization| N.R.      | N.R.      |
| Developmental toxicity   | N.R.      | N.R.      |
| Teratogenicity           | N.R.      | N.R.      |
| Testicular toxicity      | N.R.      | N.R.      |
| Adrenal gland toxicity   | N.R.      | N.R.      |
| Hepatotoxicity           | N.R.      | N.R.      |
| Ocular toxicity          | N.R.      | N.R.      |
| Pulmonary toxicity       | N.R.      | N.R.      |
| Splenotoxicity           | N.R.      | N.R.      |
| Thyroid toxicity         | N.R.      | N.R.      |
| Urolithiasis             | N.R.      | N.R.      |
| Bladder disorders        | N.R.      | N.R.      |
| Bladder urothelial hyperplasia | N.R.  | N.R.      |
| Bone marrow toxicity     | N.R.      | N.R.      |
| Cumulative effect on white cell count and immunology | N.R. |
| Bradycardia              | N.R.      | N.R.      |
| Cardiotoxicity           | N.R.      | N.R.      |
| HERG channel inhibition  | N.R.      | N.R.      |
| Kidney disorders         | N.R.      | N.R.      |
| Kidney function-related toxicity | N.R. | N.R. |
| Nephrotoxicity           | N.R.      | N.R.      |
| alpha-2-mu-Globulin nephropathy | N.R. | N.R. |
| Cholinesterase inhibition| N.R.      | N.R.      |
| Neurotoxicity            | N.R.      | N.R.      |
| 5 alpha-Reductase inhibition | N.R. | N.R. |
| Anaphylaxis              | N.R.      | N.R.      |
| Blood in urine           | N.R.      | N.R.      |
| Cerebral oedema          | N.R.      | N.R.      |
| Chloracne                | N.R.      | N.R.      |
| Cyanide-type effects     | N.R.      | N.R.      |
| High acute toxicity      | N.R.      | N.R.      |

(Continued)

TABLE 1 | Continued

|                          | Neferine  | Verapamil |
|--------------------------|-----------|-----------|
| Methaemoglobinaemia      | N.R.      | N.R.      |
| Estrogen receptor modulation | N.R.  | N.R.      |
| Estrogenticity           | N.R.      | N.R.      |
| Peroxisome proliferation | N.R.      | N.R.      |
| Phospholipidosis         | N.R.      | N.R.      |
| Phototoxicity            | N.R.      | N.R.      |
| Mitochondrial dysfunction| N.R.      | N.R.      |
| Uncoupler of oxidative phosphorylation | N.R. |
| Irritation (of the eye)  | N.R.      | N.R.      |
| Irritation (of the gastrointestinal tract) | N.R. |
| Irritation (of the respiratory tract) | N.R. |
| Irritation (of the skin) | N.R.      | N.R.      |
| Lachrymation             | N.R.      | N.R.      |
| Chromosome damage        | N.R.      | N.R.      |
| Photo-induced chromosome damage | N.R. |
| Mutagenicity             | Inactive  | Inactive  |
| Photomutagenicity        | N.R.      | N.R.      |
| Non-specific genotoxicity| N.R.      | N.R.      |
| Photo-induced non-specific genotoxicity | N.R. |
| Carcinogenicity          | N.R.      | N.R.      |
| Photocarcinogenicity     | N.R.      | N.R.      |

Values for the druggability properties that meets the limits for the preset, defined druggability properties were labelled bolded. N.R., not reported.

to conventional chemotherapy, toward a new drug, is one of the proposed mechanisms against MDR (Pluchino et al., 2012; Saeed et al., 2013). One possibility is the generation of ROS due to excessive ATP consumption to export the drug by ABC transporters. Another P-gp-independent mechanism associated with the collateral sensitivity involves the alteration of membrane structure and fluidity which lead eventually to cancer cell death because of membrane perturbation (Bonavida, 2013; Saeed et al., 2013). Moreover, cancer cells primarily rely on glycolysis to meet energy needs, and have diminished rates of oxidative phosphorylation (the Warburg effect) (Cairns et al., 2011; Pluchino et al., 2012). Neferine increased the R123 accumulation in drug-resistant cells in a comparable manner with verapamil, which is a well-known P-gp inhibitor (Haq et al., 2001; Summers et al., 2004). Intriguingly, verapamil has also been shown to induce collateral sensitivity (Laberge et al., 2009; Hamm et al., 2014). P-gp inhibition was further supported by in silico molecular docking analysis by using a human P-gp homology model based on murine P-gp as template (Kadioglu et al., 2016). Since, the crystallographic structure of murine P-gp protein has been defined (Aller et al., 2009; Gutmann et al., 2010) and is sharing ∼87% identity to human P-gp in a drug-binding competent state (Saeed et al., 2015), our model well fit to the evaluation of binding energies and docking poses of neferine.

Molecular docking studies revealed that neferine binds to the drug-binding pocket with comparable binding energies to R123. In order to simulate molecular docking in a more realistic way to the functional experiments in cells, we recently introduced a co-docking approach for P-gp inhibitors at the drug-binding domain of P-gp (Kadioglu et al., 2016). This
approach consists of two distinct phases of the interaction of substrates or inhibitors with P-gp: the first phase consists of the calculation of docking, if one compound interacts with P-gp and the second phase only takes place after P-gp interacted with another compound that is supposed to interfere with the first one. Interestingly, neferine strongly interacted with P-gp, even if R123 was pre-bound. This implies that neferine binds to the P-gp drug-binding domain without interference with R123 binding. As mentioned in Figure 6, neferine bound to another site within close proximity when R123 was pre-bound. Met68, Ile864, Val865, Ile868, Ser952, Tyr953, Phe957, Val981, Gly984, and Ala985 were the interacting amino acids in the molecular docking analyses on R123 pre-bound P-gp, which were different from the interacting amino acids for the molecular docking analyses on P-gp alone.

Numerous P-gp inhibitors have been described in the past decades (Bauer et al., 2005; Srinivas, 2016), but none of them has been approved for clinical use. This might be due to the fact that many P-gp inhibitors have not been specifically developed for this purpose, but are used for the treatment of other diseases. For example, verapamil is a calcium channel blocker employed to treat cardiovascular diseases (Haq et al., 2001; Summers et al., 2004). Therefore, novel P-gp inhibitors with higher specificity for P-gp alone are required. Considering that neferine revealed collateral sensitivity toward drug-resistant cancer cells in a comparable manner to verapamil as demonstrated by the R123 uptake experiment and that neferine interacted in silico with human P-gp strongly, even if R123 was pre-bound, neferine indeed possesses the potential as a promising drug candidate to fight against MDR. In fact, the druggability properties supported this hypothesis, since neferine met most druggability parameters as evaluated via Stardrop software (Obrezanova et al., 2008; Chadwick and Segall, 2010; Obrezanova and Segall, 2010; Segall and Chadwick, 2011). Toxicity predictions further supported the druggability potential of neferine, as it did not reveal any toxicity except equivocal skin sensitization whereas verapamil revealed plausible hERG inhibition, which is an important off-target that must be avoided during drug development (Sanguinetti and Tristani-Firouzi, 2006). Extensions to Lipinski’s rule of five parameters (logD, TPSA and number of rotatable bonds) (Veber, 2003) were also satisfied by neferine implying that neferine might possess sufficient druggability properties.

CONCLUSION

The hereto reported neferine-induced collateral sensitivity toward drug-resistant tumor cells and increased R123 uptake imply the potency of applying neferine to MDR cancers therapy which is in line with other similar in vitro findings. Different from previously reported, in which the neferine-induced rendering of P-gp activity is related to the downregulation of P-gp and/or expression of the multidrug resistance protein 1 gene (mdr-1) (Cao et al., 2004; Xiao et al., 2005; Qin et al., 2010, 2011; Huang et al., 2011a,b) we verified that the direct strong interaction between neferine and P-gp is also involved. In addition, our data further illustrated the precise docking sites between neferine and P-gp which facilitate accurate drug design and scaling down the scope of novel chemical candidates screening. Most importantly, our in silico safety evaluations of neferine indicated

**FIGURE 6 | Molecular docking analysis of neferine and R123 (A), neferine docking on R123 pre-bound human P-gp (B), R123 docking on neferine pre-bound human P-gp (C).**
a favorable toxicity profile of the compound, which justifies more detailed pre-clinical studies and provided platform for further investigation concerning the therapeutic potential of clinically using neferine upon cancer therapy.

AUTHOR CONTRIBUTIONS

TE and VW: conceived the study. OK: performed the in silico experiments. OK and TE: wrote the manuscript. BL, SM, and S-WX: performed the in vitro experiments. All the authors read the manuscript.

REFERENCES

Abdelfatah, S. A., and Efferth, T. (2015). Cytotoxicity of the indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells. *Phytomedicine* 22, 308–318. doi: 10.1016/j.phymed.2015.01.002

Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuh, R., et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. *Science* 323, 1718–1722. doi: 10.1126/science.1185750

Bauer, K. S., Karp, J. E., Garimella, T. S., Wu, S., Tan, M., and Ross, D. D. (2005). A phase I and pharmacologic study of irudinbicin, cytarine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. *Leuk. Res.* 29, 263–271. doi: 10.1016/j.leukres.2004.07.002

Bonavida, B. (2013). *Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy*: Targeted Therapies to Reverse Resistance. New York, NY: Springer. doi: 10.1007/978-1-6464-7070-0

Cairns, R. A., Harris, I. S., and Mak, T. W. (2011). Regulation of cancer cell metabolism. *Nat. Rev. Cancer* 11, 85–95. doi: 10.1038/nrc2981

Cao, J. G., Tang, X. Q., and Shi, S. H. (2004). Multidrug resistance reversal in human gastric carcinoma cells by neferine. *World J. Gastroenterol.* 10, 3062–3064.

Chadwick, A. T., and Segall, M. D. (2010). Overcoming psychological barriers to good discovery decisions. *Drug Discov. Today* 15, 561–569. doi: 10.1016/j.drudis.2010.05.007

Cragg, G. M., and Newman, D. J. (2013). Natural products: a continuing source of novel drug leads. *Biochim. Biophys. Acta* 1830, 3670–3695. doi: 10.1016/j.bbadis.2013.02.008

Efferth, T., Li, P. C., Konkimalla, V. S., and Kaina, B. (2007). From traditional Chinese medicine to rational cancer therapy. *Trends Mol. Med.* 13, 353–361. doi: 10.1016/j strmelm.2007.07.001

Eghtedar, A., Kantarjian, H., Jabbour, E., O’Brien, S., Burton, E., Garcia-Manero, G., et al. (2013). Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. *Clin. Lymphoma Myeloma Leuk.* 13, 477–484. doi: 10.1016/j.clml.2013.05.006

Gillet, J. P., Efferth, T., and Ramelow, J. (2007). Chemotherapy-induced resistance by ATP-binding cassette transporter genes. *Biochim. Biophys. Acta* 1775, 237–262. doi: 10.1016/j.bbadis.2007.05.002

Gottesman, M. M., and Ling, V. (2006). The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. *FEBS Lett.* 580, 998–1009. doi: 10.1016/j.febslet.2005.12.060

Gutmann, D. A., Ward, A., Urbatsch, I. L., Chang, G., and Van Veen, H. W. (2010). Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. *Trends Biochem. Sci.* 35, 36–42. doi: 10.1016/j.tibio.2009.07.009

Hamm, R., Sugimoto, Y., Steinmetz, H., and Efferth, T. (2014). Resistance mechanisms of cancer cells to the novel vacuolar H+-ATPase inhibitor archazolid B. *Invest. New Drugs* 32, 893–903. doi: 10.1007/s10657-014-0134-1

Haq, S., Rodrigues, M., Granegger, S., Kalinowska, W., Auerbach, L., Oberhuber, G., et al. (2001). Influence of the P-glycoprotein inhibitor verapamil on the accumulation of cationic tracers in breast cells and tissues. *Eur. J. Nucl. Med.* 28, 1049–1049.

Huang, C., Cao, P., Xie, Z., and Zhu, H. (2011a). Effect of different heating methods combined with neferine on the expressions of gammaH2AX and mdr-1/P-gp in MCF-7/Adr breast cancer cells[]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 36, 317–322. doi: 10.3969/j.issn.1672-7347.2011.04.007

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. *CA Cancer J. Clin.* 61, 69–90. doi: 10.3322/caac.20070

Jun, M. Y., Karki, R., Paudel, K. R., Sharma, B. R., Adhikari, D., and Kim, D. W. (2016). Alkaloid rich fraction from *Nelumbo nucifera* targets VSMC proliferation and migration to suppress restenosis in balloon-injured rat carotid artery. *Atherosclerosis* 248, 179–189. doi: 10.1016/j.atherosclerosis.2016.03.020

Kadioglu, O., Saeed, M. E. M., Valoti, M., Frosini, M., Sgaragli, G., and Efferth, T. (2016). Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: functional and molecular docking analyses. *Biochem. Pharmacol.* 104, 42–51. doi: 10.1016/j.bcp.2016.01.014

Kuete, V., Fouotsa, H., Mbaveng, A. T., Wibine, B., Nkenglaish, A. E., and Efferth, T. (2015). Cytotoxicity of a naturally occurring furoquinoline alkaloid and four acridone alkaloids towards multi-factorial drug-resistant cancer cells. *Phytomedicine* 22, 946–951. doi: 10.1016/j.phymed.2015.07.002

Kunihara, M., Nagai, J., Murakami, T., and Takano, M. (1998). Renal excretion of reserpine from *Rauwolfia serpentina*. *Zhong Nan Da Xue Xue Bao Yi Xue* 29, 263–271. doi: 10.1016/j.jjirsc.2007.05.002

Laberge, R. M., Ambadipudi, R., and Georges, E. (2009). P-glycoprotein (ABCB1) modulates cellular sensitivity of a multidrug resistant cell line to verapamil. *Arch. Biochem. Biophys.* 491, 53–60. doi: 10.1016/j.abb.2009.09.012

Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2012). *Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings*. New York, NY: Springer. doi: 10.1007/978-1-4419-2620-0

Mapleton, R. A., Stone, M. J., and Williams, D. H. (1992). The evolutionary role of secondary metabolites—a review. *Gene* 115, 151–157. doi: 10.1016/0378-1119(92)90553-2

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., et al. (2009). AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J. Comput. Chem.* 30, 2785–2791. doi: 10.1002/jcc.21256

Newman, D. J., and Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J. Nat. Prod.* 75, 311–335. doi: 10.1021/np200906x

Obrezanova, O., Gola, J. M. R., Champness, E. J., and Segall, M. D. (2008). Automatic QSAR modeling of ADME properties: blood-brain barrier permeation and aqueous solubility. *J. Comput. Aided Mol. Des.* 22, 431–440. doi: 10.1007/s10815-008-9193-8

Obrezanova, O., and Segall, M. D. (2010). Gaussian processes for classification: QSAR modeling of ADMET and target activity. *J. Chem. Inf. Model.* 50, 1053–1061. doi: 10.1021/ci900406x
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., and Gottesman, M. M. (2012). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98–105. doi: 10.1016/j.drup.2012.03.002

Poornima, P., Weng, C. F., and Padma, V. V. (2014). Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest. Biofactors 40, 121–131. doi: 10.1002/biof.1115

Qin, Q., Chen, X. P., Yang, Z. S., Xiao, Y. H., Min, H., and Li, Y. J. (2011). Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. Leuk. Lymphoma 52, 694–700. doi: 10.3109/10428194.2010.550075

Qin, Q., Xiao, X., and Xie, Z. (2010). [Effect of neferine combined with mdr-1 shRNA on the expression of mdr-1/P-gp in K562/A02 cell line], Zhong Nan Da Xue Xue Bao Yi Xue Ban 35, 445–450. doi: 10.3969/j.issn.1672-7347.2010.05.007

Saeed, M., Reten, H. J., and Effrer, T. (2013). “Collateral sensitivity in drug-resistant tumor cells,” in Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy, ed. B. Bonavida (New York, NY: Springer).

Saeed, M., Kadioglu, O., Khalid, H., Sugimoto, Y., and Effrer, T. (2015). Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. J. Nutr. Biochem. 26, 44–56. doi: 10.1016/j.jnutbio.2014.09.008

Sanguinetti, M. C., and Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature Rev. Cardiol. 3, 7–30. doi: 10.1038/nrc1770

Segall, M. D., and Chadwick, A. (2011). Making priors a priority. J. Comput. Aided Mol. Des. 24, 957–960. doi: 10.1007/s10822-010-9388-7

Sharma, B. R., Gautam, L. N., Adhikari, D., and Karki, R. (2017). A comprehensive review on chemical profiling of Nelumbo nucifera: potential for drug development. Phytother. Res. 31, 3–26. doi: 10.1002/ptr.5732

Siegel, R. L., Miller, K. D., and Jemal, A. (2017). Cancer statistics, 2017. CA Cancer J. Clin. 67, 7–30. doi: 10.3322/caac.21387

Sridhar, K. R., and Bhat, R. (2007). Lotus – A potential nutraceutical source. J. Agric. Technol. 3, 143–155.

Srinivas, N. R. (2016). Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: what is missing? Cancer Chemother. Pharmacol. 78, 1097–1098. doi: 10.1007/s00280-016-3044-4

Stratton, M. R., Campbell, P. J., and Futreal, P. A. (2009). The cancer genome. Nature 458, 719–724. doi: 10.1038/nature07943

Summers, M. A., Moore, J. L., and Mcauley, J. W. (2004). Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann. Pharmacother. 38, 1631–1634. doi: 10.1345/aph.1E068

Tajima, Y., Nakagawa, H., Tamura, A., Kadioglu, O., Satake, K., Mitani, Y., et al. (2014). Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine 21, 323–332. doi: 10.1016/j.phymed.2013.08.024

Veber, D. F. (2003). Molecular properties that influence the oral bioavailability of drug candidates. Abstr. Pap. Am. Chem. Soc. 225, U208.

Venkatraman, P. (2010). Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. Mini Rev. Med. Chem. 10, 540–549. doi: 10.2174/138955710791384090

Xiao, X. B., Xie, Z. X., Chen, J., Qin, Q., and Zhu, Y. (2005). [Effect of neferine on the chemotherapeutic sensitivity of STI 571 to K562/A02 cells], Zhong Nan Da Xue Xue Bao Yi Xue Ban 30, 558–561.

Xu, L., Zhang, X., Li, Y., Lu, S., Lu, S., Li, J., et al. (2016). Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/JNK activation. Tumour Biol. 37, 8721–8729. doi: 10.1007/s13277-015-4737-8

Yoon, J. S., Kim, H. M., Yadunandam, A. K., Kim, N. H., Jung, H. A., Choi, J. S., et al. (2013). Neferine isolated from Nelumbo nucifera enhances anti-cancer activities in Hep3B cells: molecular mechanisms of cell cycle arrest, ER stress induced apoptosis and anti-angiogenic response. Phytotherapy 20, 1013–1022. doi: 10.1016/j.phymed.2013.03.024

Zeino, M., Saeed, M. E. M., Kadioglu, O., and Effrer, T. (2014). The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter. Invest. New Drugs 32, 618–625. doi: 10.1007/s10637-014-0098-1

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Kadioglu, Law, Mok, Xu, Effrer and Wong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.